000			03465nas a22003735i 4500
001			3059-3689
003			DE-He213
005			20260610082530.0
007			cr nn 008mamaa
008			241030s||||||||xxkuu poo|||||| b|EN |d
022			_a3059-3689
024	7		_a44451 _2local
210	1	0	_aPsychedelic Subst. Res.
245	1	0	_aPsychedelic Substances Research _h[electronic resource] / _cedited by Louis Gautier.
264		1	_aLondon : _bBioMed Central : _bImprint: BioMed Central.
300			_bonline resource.
520			_aPsychedelic Substances Research is a fully open access, peer-reviewed journal publishing research and commentary on the use of psychedelic substances in medicine, psychology and psychotherapy. Psychedelic substances (also referred to as hallucinogens) are defined as psychoactive substances profoundly alter perception, cognition, mood, and consciousness, often producing changes in sensory experience and self-awareness. The Journal considers applications on all types of psychedelic substances, including purely synthetic compounds (such as LSD), semi-synthetic or naturally derived compounds (such as DMT), naturally occurring compounds (such as psilocybin or mescaline), preparations of plants and fungi with psychedelic properties, and substances that have specific uses in cultural, ritual and religious contexts. Substances that are not classified as hallucinogens but can produce psychedelic effects will be considered (such as ketamine or MDMA). Psychedelic Substances Research provides a resource for informed policy discussion and public discourse on the appropriate use of psychedelic substances in medicine. The journal also aims to inform the organisation of health research systems for psychedelic substances according to current national and international regulations and to foster engagement with differing cultural and religious perspectives on using psychedelic substances more broadly. Psychedelic Substances Research therefore aims to be multidisciplinary and support clinical medicine, psychology, psychiatry, neuroscience, pharmacology, biochemistry and genetics, public health, public policy, traditional medicine, anthropology, and ethnobotany. Examples of therapeutic applications include: Cognitive effects of psilocybin in patients with treatment-resistant depression Impact of psychedelic-assisted therapy on end-of-life anxiety in cancer patients MDMA-assisted psychotherapy for post-traumatic stress disorder (PTSD) Neurobiological mechanisms underlying the antidepressant effects of ketamine Cognitive performance of individuals using regular microdoses of LSD Spiritual and religious practices using ayahuasca for enhancing well-being and personal growth Effectiveness of various psychedelic substances in overcoming addiction or controlling addictive behaviours.
650		0	_aPublic health.
650		0	_aPsychiatry.
650		0	_aPharmacology.
650		0	_aNeuropharmacology.
650		0	_aAnthropology.
650		0	_aAlternative medicine.
650	1	4	_aPublic Health.
650	2	4	_aPsychiatry.
650	2	4	_aPharmacology.
650	2	4	_aNeuropharmacology.
650	2	4	_aAnthropology.
650	2	4	_aComplementary and Alternative Medicine.
700	1		_aGautier, Louis. _eeditor. _4edt _4http://id.loc.gov/vocabulary/relators/edt
710	2		_aSpringerLink (Online service)
856	4	0	_uhttps://link.springer.com/journal/44451 _zOpen Access
999			_c4237 _d4237